Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;10(3):1244-1251.
doi: 10.21037/gs-2019-ursoc-12.

Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review

Soohyun Oh  1 , Haerin Paik  1 , Soo Jin Park  1 , Eun Ji Lee  1 , Hee Seung Kim  1
Affiliations
Review

Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review

Soohyun Oh et al. Gland Surg. 2021 Mar.

Abstract

For recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis (PC), it is challenging to resect tumors completely or to get complete remission by intravenous (IV) chemotherapy, and many patients show the resistance to various chemotherapeutic agents for IV chemotherapy ultimately. As an alternative, pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced for treating the disease, which delivers chemotherapeutic agents as an aerosol form while maintaining high intraperitoneal (IP) pressure. Based on preclinical studies, PIPAC showed better penetration depth and distribution of drugs into the peritoneum in comparison to conventional IP chemotherapy. Tumor regression on histology and peritoneal carcinomatosis index (PCI) has also been shown in relevant studies. In addition, most of the PIPAC procedures were completed successfully with acceptable toxicity due to the use of a low dose of chemotherapeutic agents. For considering these advantages of PIPAC, we review the current status of PIPAC for treating recurrent ovarian, fallopian or primary peritoneal cancer through literature review.

Keywords: Pressurized; aerosol; cancer; chemotherapy; fallopian; intraperitoneal (IP); ovarian; peritoneal.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-2019-ursoc-12). The series “Ultra-Radical Surgery in Ovarian Cancer: Surgical Techniques for Gynecologic Oncologist” was commissioned by the editorial office without any funding or sponsorship. HSK serves as an unpaid editorial board member of Gland Surgery from Aug 2019 to Jul 2021. The authors have no other conflicts of interest to declare.

References

    1. Heintz A, Odicino F, Maisonneuve P, et al. Carcinoma of the Ovary. Int J Gynaecol Obstet 2006;95 Suppl 1:S161-92. 10.1016/S0020-7292(06)60033-7 - DOI - PubMed
    1. Quere P, Facy O, Manfredi S, et al. Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study. Dis Colon Rectum 2015;58:743-52. 10.1097/DCR.0000000000000412 - DOI - PubMed
    1. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 2016;14:128. 10.1186/s12957-016-0892-7 - DOI - PMC - PubMed
    1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. 10.1056/NEJMoa052985 - DOI - PubMed
    1. Knox JD, Mitchel RE, Brown DL. Effects of hyperthermia on microtubule organization and cytolytic activity of murine cytotoxic T lymphocytes. Exp Cell Res 1991;194:275-83. 10.1016/0014-4827(91)90365-2 - DOI - PubMed